Xenical ads lack balance

May 2000
Healthy Weight Journal;May/Jun2000, Vol. 14 Issue 3, p35
Deals with the letter made by the United States Food and Drug Administration (FDA) to Hoffman-LaRoche Inc. on the television advertisement of its Xenical or orlistat drug. FDA complaint on the advertisement's imbalances; Action taken by the company on the complaint.


Related Articles

  • Xenical endures ad silence as FDA forces alterations. Goetzl, David // Advertising Age;11/8/1999, Vol. 70 Issue 46, p40 

    This article reports on the changes made by U.S. drug company Hoffmann-La Roche to the direct-to-consumer advertising campaign for its obesity drug Xenical as of November 1999. The U.S. Food and Drug Administration (FDA) charged the commercial, valued at $70 million to $75 million, lacked fair...

  • FDA offers derms isotretinoin medium. Dyer, Angela // Dermatology Times;Dec2001, Vol. 22 Issue 12, PRECEDING p1 

    Focuses on the program of Roche Laboratories to prevent birth defects during the use of isotretinoin in New Jersey. Involvement of pharmacists, physicians and patients in the program; Goals being addressed in the program; Collaboration with the Food and Drug Administration for risk management...

  • Side effects prompt stronger warning on acne drug.  // FDA Consumer;May/Jun98, Vol. 32 Issue 3, p3 

    Presents information which relates to the side effects from the use of the acne drug Accutane (istretinoin) while highlighting the United States Food and Drug Administration and the drug's manufacturer, Roche Laboratories enforcing the addition of stronger warnings to the drug's label. Side...

  • Hoffmann-La Roche warned of ADE violations. Dickinson, James G. // Medical Marketing & Media;Mar1998, Vol. 33 Issue 3, p36 

    States that Hoffmann-La Roche has received a Warning Letter from the United States Food and Drug Administration. Details on the letter; Who received the letter.

  • FDA opens hearings on Xenical weight drug.  // Advertising Age;5/19/1997, Vol. 68 Issue 20, p22 

    Reveals that Roche Laboratories' weight-reducing drug called Xenical has underwent its first hearing before the US Food & Drug Administration advisory committee. The session as the first step toward full approval for marketing.

  • Roche sheds Lowe as Xenical agency. Goetzl, David; Snyder Bulik, Beth // Advertising Age;4/17/2000, Vol. 71 Issue 17, p1 

    This article reports on the decision of Hoffman-La Roche to replace the Lowe Group as the advertising agency for weight loss drug Xenical in April 2000. The account for Xenical includes an estimated $80 million direct-to-consumer business as well as physician-targeted advertising. One hurdle...

  • Roche Kicks Off Review for Xenical Fat Drug. McMains, Andrew // Adweek Eastern Edition;4/17/2000, Vol. 41 Issue 16, p4 

    Reports on Roche Laboratories has launched a review of the Xenical account at Lowe Consumer Healthcare. Creative and media duties in play; Potential side effects of Xenical.

  • FIRST CANADIAN TRIAL FOR XENICAL LAUNCHED.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p5 

    Reports that Hoffman-La Roche Limited has initiated a clinical trial to evaluate its weight loss medication Xenical in Canada.

  • Roche commits $75M to Xenical DTC campaign.  // Drug Store News;11/29/99, Vol. 21 Issue 19, p17 

    Discusses the launching of the television direct-to-consumer (DTC) program for Xenical, one of the largest DTC spends in the industry by Hoffman-La Roche Inc. Overview of the action taken by Hoffman to carry out the program; Role of the Indian Medical Society; Focus of the television campaigns.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics